Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

STAT3 oligonucleotide inhibits tumor angiogenesis in preclinical models of squamous cell carcinoma

Klein, JD and Sano, D and Sen, M and Myers, JN and Grandis, JR and Kim, S (2014) STAT3 oligonucleotide inhibits tumor angiogenesis in preclinical models of squamous cell carcinoma. PLoS ONE, 9 (1).

Published Version
Available under License : See the attached license file.

Download (1MB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Purpose: Signal transducer and activator of transcription 3 (STAT3) has shown to play a critical role in head and neck squamous cell carcinoma (HNSCC) and we have recently completed clinical trials of STAT3 decoy oligonucleotide in patients with recurrent or metastatic HNSCC. However, there is limited understanding of the role of STAT3 in modulating other aspects of tumorigenesis such as angiogenesis. In this study, we aimed to examine the effects of STAT3 decoy oligonucleotide on tumor angiogenesis. Experimental Design: A STAT3 decoy oligonucleotide and small interfering RNA (siRNA) were used to inhibit STAT3 in endothelial cells in vitro and in vivo. The biochemical effects of STAT3 inhibition were examined in conjunction with the consequences on proliferation, migration, apoptotic staining, and tubule formation. Additionally, we assessed the effects of STAT3 inhibition on tumor angiogenesis using murine xenograft models. Results: STAT3 decoy oligonucleotide decreased proliferation, induces apoptosis, decreased migration, and decreased tubule formation of endothelial cells in vitro. The STAT3 decoy oligonucleotide also inhibited tumor angiogenesis in murine tumor xenografts. Lastly, our data suggest that the antiangiogenic effects of STAT3 decoy oligonucleotide were mediatedthrough the inhibition of both STAT3 and STAT1. Conclusions: The STAT3 decoy oligonucleotidewas found to be an effective antiangiogenic agent, which is likely to contribute to the overall antitumor effects of this agent in solid tumors. Taken together with the previously demonstrated antitumor activity of this agent, STAT3 decoy oligonucleotide represents a promising single agent approach to targeting both the tumor and vascular compartments in various malignancies. © 2014 Klein et al.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Klein, JD
Sano, D
Sen, Mmas175@pitt.eduMAS175
Myers, JN
Grandis, JRjgrandis@pitt.eduJGRANDIS
Kim, S
ContributionContributors NameEmailPitt UsernameORCID
Date: 3 January 2014
Date Type: Publication
Journal or Publication Title: PLoS ONE
Volume: 9
Number: 1
DOI or Unique Handle: 10.1371/journal.pone.0081819
Schools and Programs: School of Medicine > Otolaryngology
School of Medicine > Pharmacology and Chemical Biology
Refereed: Yes
Date Deposited: 16 Jun 2014 16:37
Last Modified: 02 Feb 2019 16:58


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item